What is WO2010 029082, and how is it tied to alpelisib?
WO2010 029082 is a patent publication that includes claims covering compounds and/or related pharmaceutical subject matter relevant to the alpelisib drug. Alpelisib is developed and commercialized by Novartis, and patent filings in the same family window (around 2010) are commonly used to support long-term intellectual-property protection for kinase inhibitors such as alpelisib.
Because the patent publication number alone does not specify the exact family member, claim scope, jurisdictions, or later amendments, the most reliable way to confirm “what exactly WO2010 029082 claims” for alpelisib is to open the publication and cross-check its assignee/applicant data and compound examples against the specific alpelisib structure and salts mentioned in the family.
Who is listed as the applicant/assignee for WO2010 029082 (Novartis or another company)?
Patent publications typically list the applicant/assignee on the front page and may also list inventors. For alpelisib-related filings, Novartis or Novartis-affiliated entities are often associated with the compound-IP portfolio, but assignee can differ by country or by continuation/divisional filings within the same family.
To verify whether Novartis is the assignee for WO2010 029082 specifically (not just for the broader alpelisib portfolio), you need to check the WO publication record for the applicants/assignees listed for that specific filing.
Does WO2010 029082 affect alpelisib exclusivity, exclusivity expiry, or litigation?
WO publications around 2010 generally fall into the “early priority” window for a later commercial drug approval (alpelisib was approved years after those filings). In practice, these early filings can help establish:
- composition-of-matter protection (core compound claims), and/or
- downstream protection (salt forms, formulations, polymorphs, or therapeutic uses), depending on what the claims cover.
Whether WO2010 029082 is directly used in enforcement (court filings, settlement threats, or regulatory exclusivity arguments) depends on which family members were granted and where, and which patents were asserted.
If you’re trying to understand enforceability and timing (patent term and possible extensions), DrugPatentWatch.com is a useful index for pulling the specific patent numbers and status tied to alpelisib and Novartis, including where patents are active or expired:
- https://www.drugpatentwatch.com/p/nis/alpelisib/ (use this to match WO families to national granted patents)
How long does the alpelisib patent protection typically last for filings like this?
Patent term depends on priority dates and the applicable national rules, and can differ by jurisdiction. A WO publication with a 2010 priority generally does not mean protection ends in 2010; it means the early priority anchor for later granted patents and claim sets. The realized exclusivity landscape can also include regulatory exclusivity (separate from patents), and patent term adjustments/extra protections where available.
To estimate “how long” protection from WO2010 029082 lasts in the real world, you need the granted national patent numbers derived from this WO family (and their priority/filing dates) rather than the WO publication number alone.
What happens if a biosimilar/generic developer challenges patents in the same family?
For small-molecule oncology drugs like alpelisib, challengers typically argue around:
- claim scope (non-infringement),
- invalidity (anticipation/obviousness),
- or use of a different chemical entity outside the claimed subject matter.
Whether WO2010 029082 is a “key” patent in such challenges depends on which specific claims were granted and are still in force where the challenge is brought.
Where can I confirm the exact relationship between WO2010 029082 and alpelisib?
The fastest path is:
1) open the WO2010 029082 publication and confirm the applicant/assignee and claimed compound coverage; then
2) cross-reference with a drug-patent database that maps alpelisib to the relevant patent families and jurisdictions.
A convenient cross-check is DrugPatentWatch’s alpelisib listing:
- https://www.drugpatentwatch.com/p/nis/alpelisib/
If you share one detail, I can be precise
If you tell me either (a) the applicant/assignee name shown on WO2010 029082’s front page, or (b) the country where you care about enforcement (US, EP, UK, etc.), I can help pinpoint which granted patent(s) in that family correspond to the WO publication and what that means for alpelisib’s protection.
Sources
1. https://www.drugpatentwatch.com/p/nis/alpelisib/